New Zealand’s PHARMAC Funds J&J’s Concerta, Topamax: Australia/New Zealand Regulatory Roundup
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - New Zealand's Pharmaceutical Management Agency will now fund Johnson & Johnson's Concerta (methylphenidate extended release) for the treatment of attention deficit hyperactivity disorder, beginning Sept. 1You may also be interested in...
International Vaccine Institute Forms Partnerships To Expedite Addition Of HPV Vaccine To Asia Pacific Immunization Programs
International Vaccine Institute Forms Partnerships To Expedite Addition Of HPV Vaccine To Asia Pacific Immunization Programs
Merck, Indian Government In Talks For Gardasil Supplies; Aim To Enroll 600 For Mandatory Trials
Need a specific report? 1000+ reports available
Buy Reports